## **Core Concept**
Multiple sclerosis (MS) is a chronic autoimmune disease characterized by demyelination in the central nervous system (CNS). The treatment for MS involves disease-modifying therapies (DMTs) that aim to reduce inflammation, slow disease progression, and manage symptoms.

## **Why the Correct Answer is Right**
The correct answer involves the use of **disease-modifying therapies (DMTs)** such as **interferon beta** and **glatiramer acetate**, which are first-line treatments for MS. These medications work by reducing inflammation in the CNS, thereby slowing the progression of the disease. **Interferon beta** decreases the number of relapses and slows the progression of disability, while **glatiramer acetate** has a similar effect by modulating the immune response.

## **Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because it does not represent a recognized DMT for MS.
* **Option B:** This option is incorrect because, although it might seem plausible, it does not accurately represent a standard treatment approach for MS.
* **Option C:** This option is incorrect as it does not specify a known treatment for MS.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that **early initiation of DMTs** in patients with MS can significantly impact the long-term outcome by reducing the frequency of relapses and slowing disease progression.

## **Correct Answer:** . Interferon beta.